Clinical trial
FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00066638 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00066638 |
|---|---|
| Title | FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma |
| Official title | A Phase 2 Study of Depsipeptide in Relapsed/Refractory Multiple Myeloma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma |
| Intervention type | Drug, Other |
| Interventions | Romidepsin, Laboratory Biomarker Analysis |
| Enrollment | 50 |
| Start date | Jun 1, 2003 |
| Primary completion | May 1, 2007 |
| Completion | Mar 1, 2011 |
| First posted | Aug 7, 2003 |
| Last update posted | Mar 17, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: